Skip to main content

Table 1 Selection criteria for CRS + HIPC for peritoneal carcinomatosis from gastric cancer

From: Cytoreductive surgery and Hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial

Inclusion criteria
 − Primary or recurrent gastric adenocarcinoma
 − Histological confirmation of peritoneal carcinomatosis from gastric adenocarcinoma
 − Systemic chemotherapy and/or biological are allowed before and/or after CRS + HIPC
 − Radiotherapy is allowed before or after CRS + HIPC
 − Prior CRS + HIPC is allowed if performed more than 1 year ago
 − Age between 18 to 75 years
 − Patient Karnofsky Performance Scale (KPS) ≥ 80
 − Signed informed consent
Exclusion criteria
 − Pregnancy
 − Any malignancy other than gastric adenocarcinoma
 − Any metastatic disease other than peritoneal carcinomatosis, such as liver, pulmonary or bone metastases
 − Peritoneal carcinomatosis index (PCI) > 20 at the start of CRS
 − Impossibility to obtain complete cytoreduction (CCR-0) at the end of CRS
 − Impossibility to obtain histopathological R0 resection at the end of CRS
 − Clinical relevant ascites